Novo Nordisk A/S cut its cell therapy division, which has been trying to find a cure for type 1 diabetes, as the Ozempic maker continues to slash headcount to focus on lucrative areas of obesity and diabetes treatment.
The Danish drugmaker is seeking partners to keep developing its innovationsBloomberg Terminal, according to a statement Friday. The Borsen newspaper reported almost all of the department’s 250 employees will be laid off. Novo declined to give details.